ItalyItaly

MolMed and GSK fight bubble boy

01.08.2011

Milan/London – Italy’s MolMed SpA has signed a deal with UK-based pharmaceutical giant GlaxoSmithKline to develop a production process for a gene therapy against the rare ‘bubble boy disease’. Over the next two years, GSK will pay the Italian biotech up to EUR5.5m to work on the candidate against ADA-SCID (Adenosine Deaminase Deficiency – Severe Combined Immune Deficiency). The life-threatening disease affects approximately 350 children worldwide. ADA-SCID is caused by a mutation in a single gene that prevents the body from producing the ADA enzyme. In the treatment, which GSK acquired from San Raffaele Telethon Institute in October 2010, the faulty gene is repaired in stem cells derived from the patient’s bone marrow. Previous studies suggest the treatment is able to restore long-term immune function and protect children with ADA-SCID against severe infections. The job is very welcome at MolMed. The Milan-based biotech is still hemor­rhaging money. In the first half of 2011, the firm’s EUR1.3m in revenues were dwarfed by its EUR11.8m in operating costs – and outlay won’t drop anytime soon. In late July, MolMed announced the enrolment of the first patient in a randomised Phase II trial of its investigational anticancer drug NGR-hTNF for the treatment of platinum-resistant/refractory ovarian cancer.

ItalyItaly

04.11.2010

Rome/Milan – Together with two Italian research institutes, British drug giant Glaxo­SmithKline has begun to develop a therapy for the heriditary immune defect ADA-SCID, which affects only 350 children worldwide. Fondazione...

ItalyItaly

03.11.2010

Rome – When it comes to GMOs, the gap between Italy’s federal government and its regions that has marked the country for years is rapidly widening into a gulf. The latest rupture was on display at the October session of the...

ItalyItaly

18.09.2010

Valletta – A new Life Sciences Park is to be created on the outskirts of Malta’s capital Valletta. The EUR20m project will provide space for companies operating in biotechnology and medical sciences. The park will be located in...

ItalyItaly

17.09.2010

Verona – Scientists at Glaxo­SmithKline in Verona have discovered that specific neurons in the amygdala control how mice react to fear stimuli. When they switched off the so-called Type I cells in the animals’ amyg­dala, the mice...

ItalyItaly

29.08.2010

San Michele all’Adige – The genetic code of the Golden Delicious apple has been deciphered. Led by Riccardo Velasco at the Edmund Mach Foundation in San Michele all’Adige in Italy’s Trentino province, a team of scientists from 20...

ItalyItaly

12.07.2010

: It’s hard to be a pro-GMO campaigner in Italy. Since 2001, the regions there have not implemented the plans for coexistence that were suggested by a ministerial decree. Instead, there was a de facto Italian moratorium on GM...

ItalyItaly

10.07.2010

Milan – One of Italy’s biggest biotech players wants to raise EUR58m to boost its pipeline of cancer therapies. The round will be closed on July 16th. With operating costs of EUR22.5m and a total loss of about EUR17m in 2009,...

ItalyItaly

10.07.2010

Milan – Italian researchers have restored sight to blind patients using stem cells from the patients’ own bodies. In a study published by the New England Journal of Medicine (10.1056/NEJMoa0905955), scientists from Modena and...

ItalyItaly

13.05.2010

Rome/Maryland – The Vatican has taken a bold step into unchartered territory with its decision to finance new research into the potential use of adult stem cells for the treatment of intestinal disease and possibly other...

Displaying results 21 to 30 out of 181

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-italy/browse/2/article/molmed-and-gsk-fight-bubble-boy.html

Product of the week

Products

Events

All Events

Current issue

All issues